HS-10502 + HS-20089

HS-10502 + HS-20089 is an investigational combination therapy for advanced solid tumors. HS-10502 is a selective inhibitor of Poly(ADP-ribose) polymerase 1 (PARP1), designed to interfere with DNA repair in cancer cells, thereby enhancing the efficacy of other antitumor agents[1][2]. HS-20089 is a B7-H4-targeted antibody-drug conjugate (ADC) that delivers a tubulin inhibitor directly to tumor cells expressing B7-H4, leading to cell cycle arrest and apoptosis[4][5][6]. The combination aims to leverage the DNA-damaging effects of PARP inhibition with targeted cytotoxic delivery via ADC technology. Both drugs are being developed primarily for use in patients with advanced or refractory solid tumors, including ovarian cancer, HER2-negative breast cancer (including triple-negative breast cancer), prostate cancer, gastric cancer, and endometrial cancer[1][5][8]. The developers are Jiangsu Hansoh Pharmaceutical Group ("Hansoh Pharma"), with GSK holding exclusive rights outside China for further development and commercialization of HS-20089[6].